Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Nov 14;11:321. doi: 10.1186/s13256-017-1449-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2017

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 1 — Effect of different therapies used in our patient on hemoglobin levels. Hb hemoglobin (g/dL), intravenously administered immunoglobulin (1 treatment is 1 g/kg per day for 2 days), methylprednisolone (1 treatment is 30 mg/kg per day for 3 days), RBCs red blood cells transfusion, and rituximab (1 dose is 375 mg/m²)

Inline graphic — Effect of different therapies used in our patient on hemoglobin levels. Hb hemoglobin (g/dL), intravenously administered immunoglobulin (1 treatment is 1 g/kg per day for 2 days), methylprednisolone (1 treatment is 30 mg/kg per day for 3 days), RBCs red blood cells transfusion, and rituximab (1 dose is 375 mg/m²)